IMM vs. SBTX, COS, TRX, C4XD, DDDD, FUM, OKYO, AOR, SAR, and POLB
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), Tissue Regenix Group (TRX), C4X Discovery (C4XD), 4D pharma (DDDD), Futura Medical (FUM), OKYO Pharma (OKYO), AorTech International (AOR), Sareum (SAR), and Poolbeg Pharma (POLB). These companies are all part of the "biotechnology" industry.
ImmuPharma vs. Its Competitors
SkinBioTherapeutics (LON:SBTX) and ImmuPharma (LON:IMM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, community ranking, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.
In the previous week, ImmuPharma's average media sentiment score of 0.67 beat SkinBioTherapeutics' score of 0.00 indicating that ImmuPharma is being referred to more favorably in the news media.
ImmuPharma has lower revenue, but higher earnings than SkinBioTherapeutics. SkinBioTherapeutics is trading at a lower price-to-earnings ratio than ImmuPharma, indicating that it is currently the more affordable of the two stocks.
16.6% of SkinBioTherapeutics shares are owned by institutional investors. Comparatively, 17.4% of ImmuPharma shares are owned by institutional investors. 20.4% of SkinBioTherapeutics shares are owned by insiders. Comparatively, 48.3% of ImmuPharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
ImmuPharma has a net margin of 3,519.56% compared to SkinBioTherapeutics' net margin of -237.95%. SkinBioTherapeutics' return on equity of -115.86% beat ImmuPharma's return on equity.
SkinBioTherapeutics has a beta of 2.01, suggesting that its share price is 101% more volatile than the S&P 500. Comparatively, ImmuPharma has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.
ImmuPharma received 219 more outperform votes than SkinBioTherapeutics when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 60.26% of users gave SkinBioTherapeutics an outperform vote.
Summary
ImmuPharma beats SkinBioTherapeutics on 10 of the 14 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 6/13/2025 by MarketBeat.com Staff
Buy IMM Stock Free IMM Stock Alerts